JP2024164167A5 - - Google Patents

Download PDF

Info

Publication number
JP2024164167A5
JP2024164167A5 JP2024142687A JP2024142687A JP2024164167A5 JP 2024164167 A5 JP2024164167 A5 JP 2024164167A5 JP 2024142687 A JP2024142687 A JP 2024142687A JP 2024142687 A JP2024142687 A JP 2024142687A JP 2024164167 A5 JP2024164167 A5 JP 2024164167A5
Authority
JP
Japan
Prior art keywords
subject
sulfonylurea
pharmaceutical composition
therapeutic dose
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024142687A
Other languages
English (en)
Japanese (ja)
Other versions
JP7810762B2 (ja
JP2024164167A (ja
Filing date
Publication date
Priority claimed from JP2021022562A external-priority patent/JP2021073317A/ja
Application filed filed Critical
Publication of JP2024164167A publication Critical patent/JP2024164167A/ja
Publication of JP2024164167A5 publication Critical patent/JP2024164167A5/ja
Application granted granted Critical
Publication of JP7810762B2 publication Critical patent/JP7810762B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024142687A 2015-10-07 2024-08-23 Cns浮腫に関連する損傷または状態を処置する方法 Active JP7810762B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
US62/238,461 2015-10-07
JP2021022562A JP2021073317A (ja) 2015-10-07 2021-02-16 Cns浮腫に関連する損傷または状態を処置する方法
JP2023020327A JP7592768B2 (ja) 2015-10-07 2023-02-13 Cns浮腫に関連する損傷または状態を処置する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023020327A Division JP7592768B2 (ja) 2015-10-07 2023-02-13 Cns浮腫に関連する損傷または状態を処置する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026009068A Division JP2026069546A (ja) 2015-10-07 2026-01-22 Cns浮腫に関連する損傷または状態を処置する方法

Publications (3)

Publication Number Publication Date
JP2024164167A JP2024164167A (ja) 2024-11-26
JP2024164167A5 true JP2024164167A5 (https=) 2025-03-24
JP7810762B2 JP7810762B2 (ja) 2026-02-03

Family

ID=58488580

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018517841A Active JP7349786B2 (ja) 2015-10-07 2016-10-07 Cns浮腫に関連する損傷または状態を処置する方法
JP2021022562A Withdrawn JP2021073317A (ja) 2015-10-07 2021-02-16 Cns浮腫に関連する損傷または状態を処置する方法
JP2023020327A Active JP7592768B2 (ja) 2015-10-07 2023-02-13 Cns浮腫に関連する損傷または状態を処置する方法
JP2024142687A Active JP7810762B2 (ja) 2015-10-07 2024-08-23 Cns浮腫に関連する損傷または状態を処置する方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2018517841A Active JP7349786B2 (ja) 2015-10-07 2016-10-07 Cns浮腫に関連する損傷または状態を処置する方法
JP2021022562A Withdrawn JP2021073317A (ja) 2015-10-07 2021-02-16 Cns浮腫に関連する損傷または状態を処置する方法
JP2023020327A Active JP7592768B2 (ja) 2015-10-07 2023-02-13 Cns浮腫に関連する損傷または状態を処置する方法

Country Status (15)

Country Link
US (4) US20180280325A1 (https=)
EP (1) EP3359162B1 (https=)
JP (4) JP7349786B2 (https=)
KR (2) KR102681027B1 (https=)
CN (2) CN108348534A (https=)
AU (3) AU2016335767B2 (https=)
BR (1) BR112018006925A2 (https=)
CA (1) CA3001321A1 (https=)
EA (1) EA201890893A1 (https=)
ES (1) ES2940669T3 (https=)
HK (1) HK1257542A1 (https=)
IL (1) IL258509B2 (https=)
MA (1) MA45574A (https=)
MX (1) MX392466B (https=)
WO (1) WO2017062765A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドAeromics,Inc. 新規方法
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
MA55813A (fr) * 2019-05-02 2022-03-09 Biogen Chesapeake Llc Procédé de traitement de sujets souffrant de contusions du système nerveux central
CN120004770A (zh) * 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251389B1 (en) * 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
WO2009002832A2 (en) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
EP3339190A1 (en) * 2010-07-19 2018-06-27 Biogen Chesapeake LLC Containers for glyburide solutions
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema

Similar Documents

Publication Publication Date Title
JP2024164167A5 (https=)
CHERRILL et al. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion
Meyer et al. Treatment with glycerol of cerebral oedema due to acute cerebral infarction
Finn et al. Observations on the perioperative management of aneurysmal subarachnoid hemorrhage
WO2012060719A1 (en) A combination composition
WO2014012084A1 (en) Treatment of diabetes mellitus with carvedilol
JP7451413B2 (ja) 肥満の治療および体重管理のためのglp-1組成物
RU2009118345A (ru) Цитопротекторное, нейропротекторное, кардиопротекторное, противоишемическое, антигипоксическое, антистрессорное и адаптогенное средство, фармацевтическая композиция на его основе и способы лечения заболеваний
Vanelli et al. Treatment of diabetic ketoacidosis in children and adolescents
EP0887078A1 (en) Use of L or DL-threo-DOPS for preventing and treating the consequences of cerebral ischemia
JP4712968B2 (ja) スピカマイシンまたはその誘導体を用いた疼痛の減少法または予防法
JPH08512311A (ja) 慢性疲労症候群治療用ヒ素医薬
US8829018B2 (en) Method of restoring the incretin effect
Anderson Management of beta-adrenergic blocker poisoning
JP3968347B2 (ja) 糖尿病性神経障害用医薬組成物
JP2957618B2 (ja) アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物
WO2024098854A1 (zh) 一种胞磷胆碱药物组合物及其用途
ES2281775T3 (es) Metodo para tratar insuficiencia renal.
Ryden et al. Effects of a long-acting antiarrhythmic agent--QX-572--on therapy resistant ventricular tachyarrhythmias
RU2274448C2 (ru) Применение комбинации витаминов для лечения первичных головных болей
Thompson et al. Thyroid crisis
JPS59110621A (ja) 利尿剤
Lederman Status epilepticus
CZ170896A3 (en) The use of pentoxyphylline for preparing a medicament for treating sclerosis multiplex disease and pharmaceutical composition containing thereof
KR101296479B1 (ko) 심혈관 질환 치료를 위한 l-카르니틴 및 글루코오스의용도